BioSpace News Archive

AVROBIO, Inc. announced that the company has granted an aggregate of 58,000 restricted stock units to three new employees as inducement awards under the company’s 2019 Inducement Plan.

Bicara Therapeutics announced that it will host a virtual webinar to review the latest clinical trial data for BCA101, a first-in-class EGFR/TGFβ-trap bifunctional antibody designed to deliver superior anti-tumor efficacy with an improved therapeutic window to solid tumors.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced final results from the interventional PATHFINDER study will be presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.

NuGen Medical Devices Inc. is pleased to announce, further to its press releases of July 22, 2022 and August 10, 2022, it has closed the second tranche of its previously announced non-brokered private placement through the issuance of 2,285,763 units at a price of $0.10 per Unit for gross proceeds of $228,576.30.

InnoCare Pharma (HKEX: 09969) announced today that the first patient was dosed in the phase II registrational trial (Registry number: CTR20221519) of tafasitamab in combination with lenalidomide for adult patients in China who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and are not eligible for autologous stem cell transplantation (ASCT).

Post-traumatic stress disorder (PTSD) refers to a psychological condition that affects people of any gender or age group.

The C-reactive protein testing market is predicted to display sluggish growth over the forecast period of 2020 to 2030.

Detailed positive results from the Phase 3 PRIME trial evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis were presented today in a late-breaking session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress.

The GelMA Company, a biotechnology start-up that produces high-quality biomaterials using a patented process, is excited to announce that it has secured a $510,000 contract with its new customer and strategic partner, the Government of Canada.